Articles by ‘Iain Butler’

post  |  03:07:20

EBITDAC is the new acronym which has been much discussed recently as businesses and their advisers get to grips with how to adjust valuations to take into account the impact of Covid-19. Does this further increase uncertainty in an already unsettled M&A market and how much are we really going to see it used?

Read more
post  |  16:06:20

There has been a lot for private equity (PE) funders to deal with in the wake of the Covid-19 pandemic. Understandably short-term focus has been on supporting existing portfolio companies, but the expertise and resilience of PE funders (and their advisers) combined with a strong appetite to do deals means that PE-backed buy-outs and bolt-on acquisitions are likely to have a central role in the drive towards recovery.

Read more
post  |  06:04:20

Testing is currently on top of the Government’s agenda in its efforts to slow down the coronavirus pandemic.

The spotlight is now very much on the UK’s life sciences sector and we’re very proud that our client Oxford Genetics (trading as OXGENE) has formed a strategic partnership with The Native Antigen Company Limited (NAC), another portfolio company backed by Mercia Asset Management, to scale up production of Covid-19 antigens to test for the disease.

Read more
Opinion  |  25:03:20

Companies House have updated their policy so that if accounts are not able to be filed on time due to the company being affected by Coronavirus, the company may make an application before their deadline to extend the period allowed for filing. Upon application, the company will receive an automatic and immediate 3 month extension to file their accounts.

Read more
post  |  01:04:19

Corporate lawyers from RWK Goodman have helped Oxford Genetics, an Oxford based biotechnology business which specialises in biological drug development, to secure a £6.5m syndicated investment which will further secure its position as a market-leading innovator of synthetic biology-based technologies. The cash injection values Oxford Genetics, which is based at Oxford Science Park, at £30.5m.

Read more
Show more